28.09

4.91% -1.45

Rigel Pharmaceuticals (RIGL)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rigel Pharmaceuticals stock is traded at $28.09, with a volume of 465.20K. It is down -4.91% in the last 24 hours and up +2.03% over the past month. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.

Previous Close:

$29.54

Open:

$29.54

24h Volume:

465.20K

Relative Volume:

1.35

Market Cap:

$519.10M

Revenue:

$294.28M

Net Income/Loss:

$367.02M

P/E Ratio:

1.4853

EPS:

18.9115

Net Cash Flow:

$75.66M

1W Performance:

-8.08%

1M Performance:

+2.03%

6M Performance:

-25.79%

1Y Performance:

+46.99%

1-Day Range:

$27.70

$30.06

1-Week Range:

$27.70

$30.41

52-Week Range:

$16.88

$52.24

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name

Rigel Pharmaceuticals

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

650-624-1100

Address

611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA

Employee

174

Twitter

@rigelpharma

Next Earnings Date

2026-05-05

Latest SEC Filings

RIGL's Discussions on Twitter

Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RIGL Rigel Pharmaceuticals	28.09	519.10M	294.28M	367.02M	75.66M	18.91
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-05-25	Upgrade	Jefferies	Hold → Buy
Apr-03-23	Resumed	Piper Sandler	Neutral
Jun-09-22	Downgrade	Citigroup	Buy → Neutral
Jun-08-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-08-22	Downgrade	Piper Sandler	Overweight → Neutral
Mar-23-22	Initiated	B. Riley Securities	Neutral
Nov-09-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-15-19	Resumed	Cantor Fitzgerald	Overweight
Sep-26-19	Resumed	JP Morgan	Overweight
Mar-01-19	Reiterated	Cantor Fitzgerald	Overweight
Aug-27-18	Initiated	Citigroup	Buy
May-02-18	Reiterated	Cantor Fitzgerald	Overweight
Dec-21-17	Resumed	Piper Jaffray	Overweight
Dec-15-17	Initiated	Cantor Fitzgerald	Overweight
Nov-06-17	Resumed	H.C. Wainwright	Buy
Mar-09-17	Reiterated	H.C. Wainwright	Buy
Aug-31-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Reiterated	Piper Jaffray	Overweight
Jul-13-16	Initiated	H.C. Wainwright	Buy
Jun-13-16	Initiated	Piper Jaffray	Overweight
Apr-22-16	Upgrade	JP Morgan	Neutral → Overweight
Apr-08-13	Reiterated	Stifel	Buy
Nov-29-12	Initiated	UBS	Neutral
Nov-06-12	Reiterated	Oppenheimer	Outperform
Mar-26-12	Initiated	Canaccord Genuity	Hold
Dec-10-10	Downgrade	MP Advisors	Outperform → Market Perform

View All

Rigel Pharmaceuticals Stock (RIGL) Latest News

May 05, 2026

Rigel Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance

May 05, 2026

Rigel Pharmaceuticals reports Q1 EPS 44c, consensus 87c - TipRanks

May 05, 2026

Rigel Pharmaceuticals : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q) - marketscreener.com

May 05, 2026